Effect of Lucinactant on Mucus Clearance in Cystic Fibrosis Lung Disease

Completed · Phase 2 · Has a placebo group

Conditions studied: Cystic Fibrosis

In brief

Mucus clearance is impaired in cystic fibrosis. Inhaled surfactants may reduce adhesive forces between mucus and airway surfaces and improve mucus clearance. This in turn my improve lung health. The investigators propose to measure mucus clearance before and after lucinactant or vehicle administration in patients with cystic fibrosis.

Key facts

Study ID

NCT00934362

Run by

University of North Carolina, Chapel Hill

People needed

16

Starts

2008-10-01

Expected to finish

2010-08-01

Last updated by the study team

2017-03-13

Who can join

Age: 14 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Cystic fibrosis
• FEV1>40%

You may not qualify if…

• Unstable lung disease
• Unable or unwilling to stop hypertonic saline and dornase alfa for 3 days prior to each study period
• Relevant drug allergy or intolerance
• Recent investigational drug use (30 days)

Where it is running

• University of North Carolina — Chapel Hill, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.